Area firm wins $2M investment to pursue Alzheimer's drug

Alzamend Neuro gets investment week after FDA approves Phase 1 study of AL001

FILE: Alzamend Neuro moving forward with Phase 1 clinical study of AL001, a treatment for Alzheimer’s disease and dementia.
FILE: Alzamend Neuro moving forward with Phase 1 clinical study of AL001, a treatment for Alzheimer’s disease and dementia.
  • Tampa Bay-Lakeland
  • Share

TAMPA —Alzamend Neuro has landed new investment money on the heels of the U.S. Food and Drug Administration’s approval to move forward with the testing of a drug to treat dementia and Alzheimer’s disease.

 

Continue reading your article
with a Business Observer subscription.
What's included:
  • ✓ Unlimited digital access to BusinessObserverFL.com
  • ✓ E-Newspaper app, digital replica of print edition
  • ✓ Mailed print newspaper every Friday (optional)
  • ✓ Newsletter of daily business news
Subscribe

Already subscribed? Sign in.

Latest News

  • February 22, 2026
Report: Florida ranks No. 2 in statewide foreclosure pressure
  • February 21, 2026
Retired attorney, family donate $10M to Naples hospital
  • February 20, 2026
Fort Myers portfolio sells for $30 million
  • February 20, 2026
Port Charlotte industrial portfolio gets nearly $4 million refinancing

Sponsored Content